Drugs Containing Excipient (Inactive Ingredient) UREA

« Back to Dashboard

Branded drugs containing UREA excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	LIDODERM	lidocaine	16590-141	UREA
Rebel Distributors Corp	LIDODERM	lidocaine	21695-075	UREA
STAT Rx USA LLC	LIDODERM	lidocaine	42549-576	UREA

Generic drugs containing UREA excipient

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	lidocaine	0591-2679	UREA
Actavis Pharma Inc	lidocaine	0591-3525	UREA
STAT RX USA LLC	lidocaine	16590-141	UREA

Urea Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 16, 2026

Urea is a low-cost, high-volume chemical with a small but commercially important pharmaceutical-grade segment. Its main pharmaceutical use is in topical dermatology, where it acts as a humectant and keratolytic in creams, lotions, gels, and ointments. The core molecule is commoditized and has no meaningful composition-of-matter patent protection. Supplier differentiation comes from purity, particle characteristics, microbial control, documentation, regulatory qualification, and reliable supply.

The financial outlook for pharmaceutical-grade urea is stable rather than high-growth. Revenue growth should track topical dermatology demand, private-label product expansion, geographic access to prescription skin-care products, and modest formulation innovation. Producer profitability remains exposed to ammonia, natural-gas, carbon-dioxide, energy, freight, and regulatory-compliance costs because most urea is manufactured in large fertilizer-oriented plants.

What is urea used for in pharmaceutical formulations?

Urea, CAS Registry Number 57-13-6, is used primarily in topical products. Its function changes with concentration and formulation design.

Urea concentration	Principal formulation role	Common pharmaceutical use
2%-10%	Humectant and skin-conditioning agent	Dry skin, xerosis, moisturizers
10%-20%	Humectant with mild keratolytic action	Ichthyosis, eczema-associated dryness, psoriasis
20%-40%	Strong keratolytic and emollient adjunct	Hyperkeratosis, cracked heels, calluses, nail disorders
40% or higher	Intensive keratolytic action	Severe hyperkeratosis and selected onychodystrophy products

Urea increases water retention in the stratum corneum and can weaken hydrogen bonding in keratin. At higher concentrations, this softens thickened skin and improves desquamation. Product performance depends on concentration, vehicle, pH, occlusivity, packaging, and the condition of the skin barrier.

Urea is also used in some oral, parenteral, diagnostic, and laboratory applications, but topical dermatology is the principal pharmaceutical-excipient opportunity. In many products, urea is both an excipient and the active ingredient. The legal classification depends on the product's labeling, concentration, intended use, and jurisdiction.

Which dosage forms use urea?

The most common dosage forms are:

• Creams
• Lotions
• Ointments
• Gels
• Foams
• Nail solutions
• Foot-care preparations
• Cleansing and dermatological washes

Creams and lotions account for the broadest commercial use because they support both moisturization and keratolytic positioning. High-concentration urea products often use aluminum tubes, laminated tubes, airless pumps, or other packaging that limits water loss and contamination.

How large is the pharmaceutical-grade urea market?

A precise global market size for pharmaceutical-grade urea is not publicly established. Public market reports generally combine urea across fertilizer, industrial, cosmetic, medical, and pharmaceutical uses, or group it within a broader excipient category. Public company filings rarely report pharmaceutical-grade urea revenue separately.

The market is best understood as a niche premium segment inside the much larger global urea industry.

Market layer	Economic characteristics
Agricultural urea	Largest volume segment; highly cyclical and price-sensitive
Industrial urea	Used in resins, emissions control, chemical processing, and other applications
Cosmetic-grade urea	Broader consumer and professional skin-care demand
Pharmaceutical-grade urea	Lower volume, higher documentation and qualification requirements
Finished urea dermatology products	Higher value capture through formulation, branding, regulatory approval, and distribution

The pharmaceutical segment does not control urea pricing. Instead, it inherits the cost structure of commodity urea while earning a quality and compliance premium. That premium can be meaningful per kilogram but does not eliminate exposure to global nitrogen-market conditions.

The main demand drivers are:

1. Growth in dermatology and podiatry treatment.
2. Higher prevalence of diabetes-related foot dryness and hyperkeratosis.
3. Expansion of over-the-counter and private-label skin-care products.
4. Greater use of topical products in aging populations.
5. Formulation demand for preservative-light and fragrance-free products.
6. Increased pharmacy and e-commerce distribution of high-strength moisturizers.

What is driving the financial trajectory for pharmaceutical-grade urea?

The financial trajectory is likely to be low-to-moderate revenue growth with volatile gross margins. Volume growth can be positive even when supplier revenue declines because urea prices may fall faster than demand rises.

Feedstock and energy costs

Industrial urea is produced from ammonia and carbon dioxide. Ammonia production is energy-intensive and depends heavily on natural gas in many regions. Higher gas prices increase the cost base for urea producers. Lower gas prices can improve supply and reduce selling prices.

Commodity urea prices are affected by:

• Natural-gas and coal prices
• Ammonia availability
• Fertilizer planting cycles
• Chinese export policy
• Sanctions and trade restrictions
• Shipping costs
• Port inventories
• Government fertilizer subsidies
• Seasonal agricultural demand

Pharmaceutical-grade suppliers generally buy from qualified chemical producers or operate purification and packaging systems. Their selling prices are less volatile than fertilizer-grade spot prices because customers qualify suppliers and often buy under annual contracts. The cost pass-through, however, is not unlimited.

Premium conversion economics

The economic value is created through processing and compliance rather than through the urea molecule itself. A pharmaceutical-grade supplier may incur costs for:

• Additional purification
• Controlled crystallization or milling
• Microbial and endotoxin testing where relevant
• GMP documentation
• Pharmacopoeial testing
• Change-control management
• Stability data
• Batch traceability
• Regulatory questionnaires
• Audits and customer qualification

These requirements create switching costs for pharmaceutical customers. They also limit the number of suppliers that can immediately replace an approved source.

Margin outlook

The likely margin pattern is:

Period	Revenue driver	Margin pressure
Commodity price upcycle	Higher selling prices and inventory gains	Input-cost lag and customer resistance
Commodity price downcycle	Lower unit prices	Inventory write-downs and weak price realization
Stable commodity market	Formulation and volume growth	Compliance and logistics costs
Supply disruption	Short-term price increases	Qualification limits and allocation risk

The strongest financial position belongs to suppliers with integrated nitrogen production, diversified chemical portfolios, regional warehousing, and established pharmaceutical customer approvals. Distributors can generate attractive service margins but remain exposed to manufacturer availability and customer substitution.

Which companies supply pharmaceutical-grade urea?

The market is fragmented between integrated chemical producers, specialty excipient suppliers, laboratory-chemical companies, and regional distributors. Supplier availability differs by jurisdiction and by whether the customer requires USP-NF, Ph. Eur., BP, JP, or another standard.

Relevant supplier categories include:

• Large nitrogen and chemical producers
• Specialty excipient manufacturers
• Contract powder processors
• Pharmaceutical raw-material distributors
• Laboratory and research-chemical suppliers
• Cosmetic ingredient suppliers with pharmaceutical documentation

Companies such as BASF, Merck, Avantor, Spectrum Chemical, Fagron, and regional excipient distributors have marketed urea products or pharmaceutical raw materials in various jurisdictions. Product availability, manufacturing site, compendial status, and regulatory documentation must be confirmed by product-specific technical files. A catalog listing alone does not establish that a product is suitable for an approved medicinal product.

What supplier qualifications matter most?

Pharmaceutical customers typically assess:

• Identity and assay
• Water content
• Bioburden
• Residual solvents
• Heavy metals and elemental impurities
• Particle-size distribution
• Polymorphic or crystalline form
• Microbial limits
• Nitrite and nitrate-related impurities where relevant
• Packaging integrity
• Supply continuity
• GMP and quality-system controls

Urea can hydrolyze under unfavorable conditions and may generate ammonia. Moisture, temperature, pH, and packaging therefore affect stability and odor control. The required specification depends on the finished product and route of administration.

What regulatory status does urea have in pharmaceutical products?

Urea is listed in pharmaceutical compendia and appears in drug products across multiple jurisdictions. Its regulatory status depends on whether it is declared as an active ingredient or inactive ingredient.

The U.S. Food and Drug Administration's Inactive Ingredient Database is a key reference for determining prior use in approved drug products, but an IID listing does not create a blanket approval for every route, concentration, or formulation [1].

Urea products may be marketed as:

• Prescription drugs
• Over-the-counter products
• Medical devices in certain jurisdiction-specific formulations
• Cosmetics
• Compounded preparations

A topical product that makes therapeutic claims generally requires a drug pathway. A product marketed only for cosmetic moisturization may fall under cosmetic rules, subject to local regulations and claims restrictions.

What is the Orange Book status of urea?

Urea is not protected by an Orange Book-listed composition-of-matter patent. The Orange Book lists approved drug products and applicable patents submitted by sponsors, not excipient substances as a standalone category [2].

A finished prescription product containing urea could theoretically have formulation, method-of-use, or packaging patents. Those patents would attach to the specific drug product, not to urea as a chemical substance.

What patents protect pharmaceutical urea formulations?

Urea itself is an old, well-known compound and is effectively outside modern composition-of-matter exclusivity. Patent protection can still arise around a specific formulation or use.

Potentially protectable subject matter includes:

• High-strength urea cream vehicles
• Urea combined with corticosteroids, salicylic acid, lactic acid, or ceramides
• Nail-treatment compositions
• Controlled-release topical systems
• Transdermal delivery systems
• Low-irritation formulations
• Preservative-free packaging
• Stabilized aqueous systems
• Specific particle-size or crystalline forms
• Manufacturing methods that improve stability or texture
• Treatment of a defined dermatological condition

Patent strength is usually modest for conventional urea creams because the active ingredient, concentrations, vehicles, and uses are widely disclosed. A defensible estate would need a narrow technical distinction supported by comparative data, such as improved stability, reduced irritation, enhanced penetration, or superior clinical outcomes.

Are there Paragraph IV challenges for urea products?

Paragraph IV litigation is unlikely to be a major market issue for conventional urea topical products. It becomes relevant only when a branded prescription product has an approved generic pathway and Orange Book-listed patents.

For standard urea creams, generic entry is usually driven by:

• ANDA or abbreviated regulatory filing
• State-level compounding
• OTC competition
• Private-label launch
• Formulation similarity
• Distribution access

The main competitive barrier is not patent exclusion. It is regulatory approval, manufacturing qualification, brand recognition, clinical positioning, and retailer access.

When does urea lose exclusivity?

Urea has no meaningful molecule-level exclusivity period remaining. Generic and multi-source competition is already established.

Exclusivity category	Status for urea
Composition-of-matter patent	Expired or unavailable for modern commercial purposes
Regulatory exclusivity for the molecule	Not applicable as a new chemical entity
Orange Book exclusivity	Product-specific, not molecule-wide
Formulation patents	Possible but narrow and product-specific
Method-of-use patents	Possible but generally limited
Trade-secret protection	Possible for process controls and formulation know-how
Supplier qualification protection	Commercially meaningful but not statutory exclusivity

A new urea-containing product may receive exclusivity only through a novel formulation, a regulated drug application, a device combination, or a patentable therapeutic method. Such protection would not prevent competitors from selling other urea products.

How strong are the manufacturing and intellectual-property barriers?

Manufacturing barriers are moderate at the pharmaceutical-grade level and low at the commodity level.

Low barriers

• Urea is inexpensive and widely available.
• The chemical synthesis is mature.
• Multiple global producers exist.
• The molecule is not difficult to identify or assay.
• Conventional topical formulations are easy to reproduce.

Moderate barriers

• Pharmacopoeial compliance
• Controlled impurity profile
• Stable particle size
• GMP documentation
• Customer audits
• Validated packaging
• Consistent supply
• Regulatory change control

Higher barriers for specific products

• Sterile or highly controlled applications
• Novel delivery systems
• Clinical claims supported by comparative data
• Combination products with multiple active ingredients
• Products requiring device or drug-device approval
• Formulations with proprietary manufacturing processes

The result is a market with low chemical barriers but meaningful qualification and execution barriers.

How does urea compare with competing dermatology excipients?

Urea competes with glycerin, propylene glycol, lactic acid, ammonium lactate, petrolatum, mineral oil, ceramides, and hyaluronic acid.

Ingredient	Primary function	Cost position	Differentiation
Urea	Humectant and keratolytic	Low	Concentration-dependent clinical utility
Glycerin	Humectant	Low	Broad formulation compatibility
Petrolatum	Occlusive emollient	Low	Strong barrier effect
Lactic acid	Humectant and keratolytic	Low to moderate	Acidic pH and irritation trade-off
Ammonium lactate	Humectant and keratolytic	Moderate	Established dermatology use
Ceramides	Barrier repair	Moderate to high	Formulation and branding differentiation
Hyaluronic acid	Humectant and film former	Moderate to high	Cosmetic and premium positioning

Urea has a favorable value proposition because it combines moisturization with keratolytic action at a relatively low raw-material cost. Its limitations include possible stinging on damaged skin, odor concerns in some formulations, and sensitivity to formulation conditions.

What generic launch risks exist for urea products?

Generic-entry risk is high for conventional urea formulations and lower for differentiated products.

High-risk products

• Standard 10% or 20% creams
• Basic 40% foot creams
• Generic lotions
• Simple urea ointments
• Products with no patent-protected delivery system

Moderate-risk products

• Prescription-strength combination products
• High-concentration nail formulations
• Products with specialized packaging
• Products supported by clinical differentiation

Lower near-term substitution risk

• Branded products with strong dermatology distribution
• Products bundled with devices
• Products requiring a proprietary applicator
• Formulations with validated stability or tolerability advantages
• Products supported by payer or institutional contracts

Retail and pharmacy buyers can change suppliers rapidly when the formulation is simple. Manufacturer qualification and regulatory documentation slow substitution but rarely prevent it permanently.

What licensing deals affect the urea excipient market?

Licensing activity is generally concentrated at the finished-product level rather than at the raw-material level. Urea suppliers usually sell through supply agreements, quality agreements, distribution contracts, and private-label arrangements rather than classic patent licenses.

Commercial transactions may include:

• Exclusive regional distribution
• Contract manufacturing
• Private-label dermatology products
• Co-development of combination creams
• Technology transfer for high-concentration formulations
• Supply agreements tied to approved manufacturing sites

Public disclosures rarely identify the portion of a licensing payment attributable to urea. The economic value generally resides in the finished formulation, brand, regulatory file, or distribution network.

What is the competitive landscape for urea dermatology products?

Competition is broad and includes:

• Dermatology-focused pharmaceutical companies
• Consumer health companies
• Generic-drug manufacturers
• Pharmacy chains
• Medical-device companies
• Cosmetic brands
• Hospital and compounding pharmacies

The market is divided between prescription dermatology, OTC treatment, professional foot care, and cosmetic moisturization. Prescription products compete on clinical positioning and reimbursement. OTC products compete on price, concentration, texture, packaging, and retailer placement.

The most durable commercial advantages are:

1. Dermatologist recommendation.
2. Consistent product feel and tolerability.
3. High-concentration performance.
4. Brand trust.
5. Retail distribution.
6. Private-label manufacturing capacity.
7. Reliable regulatory documentation.

What is the revenue exposure for urea suppliers?

Urea revenue is usually immaterial to diversified nitrogen and chemical companies. For specialty excipient distributors, it can be a recurring but relatively small product line. The value chain is more attractive for finished-product manufacturers than for bulk urea producers.

Revenue exposure is highest for:

• Specialty excipient distributors
• Dermatology contract manufacturers
• Private-label skin-care companies
• Generic topical-drug manufacturers
• Suppliers with validated pharmaceutical-grade production

Revenue exposure is lowest for:

• Integrated fertilizer producers
• Large commodity chemical groups
• Companies selling urea primarily into agriculture
• Broadline distributors with thousands of raw materials

Standalone financial forecasts for pharmaceutical-grade urea are therefore less reliable than forecasts for the broader nitrogen, excipient, or topical-dermatology markets.

What is the likely five-year financial trajectory?

The base case is steady volume growth, limited pricing power, and margin volatility.

Scenario	Demand	Pricing	Supplier profitability
Base case	Low-single-digit growth	Stable to modestly declining	Stable
Upside case	Strong dermatology and private-label expansion	Premium maintained	Improved
Downside case	Weak consumer demand and excess supply	Commodity-price pressure	Compressed
Supply-shock case	Product availability tightens	Sharp short-term increase	Mixed due to input costs

The best-performing suppliers should be those that combine pharmaceutical-grade documentation with regional inventory and reliable delivery. Pure commodity producers will remain dependent on nitrogen-market conditions. Finished-product companies can capture more value through branded, clinically positioned, or combination products.

Key Takeaways

• Urea is a mature, low-cost pharmaceutical excipient and topical active ingredient.
• Its principal pharmaceutical use is in dermatology, especially creams, lotions, ointments, gels, and nail products.
• Urea has no meaningful molecule-level patent exclusivity.
• Formulation, method-of-use, packaging, and manufacturing patents can protect specific finished products.
• Orange Book and Paragraph IV issues are product-specific and limited for conventional urea formulations.
• Pharmaceutical-grade economics depend on qualification, documentation, purification, and supply reliability.
• The market has low chemical barriers but moderate regulatory and customer-approval barriers.
• Revenue growth should be steady but modest, while margins remain exposed to ammonia, natural-gas, energy, and fertilizer-market cycles.
• The strongest value capture occurs in finished dermatology products, private-label manufacturing, and specialized distribution rather than bulk urea production.

FAQs About Pharmaceutical-Grade Urea

Is urea an active pharmaceutical ingredient or an excipient?

It can be either. In a 10% or 40% dermatology cream marketed to treat a defined condition, urea may be the active ingredient. In another formulation, it may function as a humectant or stabilizing excipient.

Is pharmaceutical-grade urea different from fertilizer-grade urea?

Yes. The chemical identity is the same, but pharmaceutical-grade material requires tighter control of impurities, documentation, testing, traceability, packaging, and manufacturing conditions. Fertilizer-grade urea is not automatically suitable for medicinal use.

Can a company patent a 40% urea cream?

A basic 40% urea cream is unlikely to support a strong broad patent because similar concentrations and vehicles are well known. A patent may be possible for a technically distinct vehicle, delivery system, stability improvement, combination, or manufacturing method.

Is urea affected by biosimilar competition?

No. Biosimilars apply to biological products. Urea is a small-molecule chemical and competes through generic, OTC, private-label, and branded formulation channels.

What is the main investment risk in pharmaceutical-grade urea?

The main risk is limited pricing power combined with exposure to commodity input costs. A supplier without differentiated documentation, qualified manufacturing capacity, or finished-product ownership may capture only a small portion of the value created downstream.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive ingredient search for approved drug products. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary: Urea monograph. U.S. Pharmacopeial Convention.

4. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia: Urea monograph. Council of Europe.

5. U.S. Food and Drug Administration. (2009). Guidance for industry: Q7A good manufacturing practice guidance for active pharmaceutical ingredients. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7a-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients

6. International Fertilizer Association. (2024). Urea production, markets, and global fertilizer industry data. https://www.fertilizer.org

7. World Bank. (2024). Commodity markets outlook and fertilizer price data. https://www.worldbank.org/en/research/commodity-markets